Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.
You may also be interested in...
Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks
Is benefit/risk profile in squamous non-small cell lung cancer impacted by Phase III results from trial in non-squamous population that was halted early due to safety issues?
Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.